$OMHE 34+ PAGE DUE DILIGENCE BOTTOM PLAY TRIPLE 0'S

34+ PAGE DUE DILIGENCE PACKET

L2:




CURRENT ISSUES WITH COMPANY:
NVSOS=DELINQUENT
DELEWARE SUBS DELINQUENT "ENTOURAGE BIOTECH, AGELOCK BIOTECH, CELEBRITY BRANDS LLC, LX RETAIL GROUP INC".
pending suit for violation of promissory note "due to form 15 filing"

STILL WORTH A WATCH-LIST RECOMMENDATION MINIMUM.

$TRBO Priced at 7 cents its a no brainer was at $2.70

$GBHL Bottom Chart Play - Nice volume last few days.

Bullish Chart
https://www.barchart.com/stocks/quotes/GBHL/technical-chart?plot=BAR&volume=total&data=DO&density=M&pricesOn=1&asPctChange=0&logscale=0&indicators=SMA(10);SMA(50);SMA(200);RSI(14,100);ACCUM;MFI(14,100);SMACD(12,26,9)&sym=GBHL&grid=1&height=500&studyheight=100

UATG

Volume 7,393,000

Up $0.0002 $0.0019

$WRFX. Bottom

$ZNGY: could run like TT** (II), MG*

JETMF

$EMLL: $.0001s play

$SMPI - Trading Green On Breaking News Keep Watch

Is this the best place to put your money?



I say go with USLV.

$SMPI - Bottom Bounce Play Looking Solid

Trivago N.V. ADS (TRVG)
6.84 0.37 (5.72%)

Downside risk is almost nil.

My BOTTOM PLAYS did not pan out.

I will switch my strategy.

CDE still holding
UAA out
TRVG out
AMD still holding
VRX piled in

Valeant: Vyzulta Approval Actually Big News

Nov. 7, 2017 12:23 PM ET Seeking Alpha

FDA approved the NDA for Vyzulta after Valeant cleared the necessary hurdles.

A quick look at the market opportunity for the drug.

It's hard to criticize Valeant's pipeline when it continues to produce new commercial products and advances in other notable candidates.

Can new revenue streams make a meaningful difference for Valeant's earnings?

Valeant Pharmaceuticals International Inc. (VRX) got its long awaited approval for Vyzulta after working out the issues affecting its Tampa, Fla., manufacturing facility. Valeant expects to get Vyzulta on the market as quickly as possible with a good chance at grabbing some key market share in 2018, as there is a sizable opportunity for the drug given its advantages over competition. Criticizing Valeant's pipeline of drugs gets harder and harder for bears to do when the company continues to successfully bring new products to commercial viability while advancing early stage candidates at a rapid pace.

The FDA approved the New Drug Application for Vyzulta (latanoprostene bunod ophthalmic solution, 0.024%) as the first prostaglandin analog with one of its metabolites being nitric oxide. It is indicated for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. This is fine and dandy, but what I always want to know is what sets it apart from the competition and can it grab market share in the coming years. Vyzulta is a molecule with a dual mechanism of action that creates significant, consistent and sustained (IOP) reduction over a 12-month period. It has shown multiple statistically significant results in IOP lowering and efficacy compared to other glaucoma drugs and will look to grab market share from key glaucoma players in the space including Pfizer (PFE), Novartis (NVS), and Allergan (AGN).

The drug approval has been on hold since August when Valeant got a Complete Response Letter from the FDA citing Current Good Manufacturing Practice (CGMP) issues with the company's manufacturing facility in Tampa, Fl. These issues got cleared up when Valeant got a Voluntary Action Indicated (VAI) inspection classification later in August mentioning that the facility still had concerns, but that those concerns were below the threshold of regulatory significance. With all the regulatory issues cleared up, Valeant CEO Joseph Papa was confident enough to state that "We expect to make this new advancement available for those who suffer with glaucoma before the end of the year."

Now, what does the market look like for Vyzulta in 2018 when it attempts to seize market share from its competition? According to Valeant, the company estimates approximately 3 million people in the U.S. suffer from glaucoma with a total glaucoma market opportunity at close to $3 billion. Prostaglandin-analog class drugs, such as Vyzulta, account for roughly $1.6 billion of the total market with about 17 million prescriptions written annually.

Having a superior product, in many respects, to a lot of the competition entering a $1.6 billion dollar market is a big deal. This is just one of Valeant's new products that looks to make a significant impact on sales growth in the coming years with the possibility that Siliq also might make a meaningful impact on dermatology sales. Other pipeline progressions also continue including the latest FDA acceptance of Valeant's marketing application for IDP-118 (halobetasol propionate and tazarotene) lotion for the topical treatment of plaque psoriasis with a June 18, 2018, action date.

Finally, will new commercial products like Vyzulta and Siliq move the needle for Valeant as they both look to seize share in billion-dollar market niches? The company is focused on paying down debt by selling non-core assets and growing revenues as it continues its turnaround strategy so new meaningful revenue streams would be crucial. Here are some revenue and EBITDA numbers over the last year along with the revenue numbers for Dermatology (Siliq) and the company's Bausch + Lomb/International (Vyzulta) segments.

Valeant Revenues Adj. EBITDA Dermatology B + L
Q2, 2017 2.23B 951M 130M 1.24B
Q1, 2017 2.11B 861M 192M 1.15B
Q4, 2016 2.40B 1.05B 214M 1.18B
Q3, 2016 2.48B 1.16B 223M 1.16B
Q2, 2016 2.42B 1.09B 188M 1.28B

As Valeant focuses on aggressively paying down its debt load, growing revenues with new products like Vyzulta will have a chance to produce meaningful new revenue streams that will potentially make a difference, not only in their respective segments but on the company's earnings as a whole. I look for Vyzulta in particular to start making a big splash especially in the second half of 2018. If Valeant can show some consistent growth and momentum next year with new growing revenue streams, look for market sentiment to finally start to shift positive as the company's debt burden continues to shrink. Best of luck to all.

Under Armour to make MLB uniforms in 2019, a year early

May 19, 2017 ESPN.com news services

NEW YORK -- Under Armour and Fanatics will take over for Majestic and Nike as the official uniform partners for Major League Baseball in 2019, a year earlier than previously scheduled.

Under Armour, Fanatics' uniform deal announced

The on-field deal between MLB, Under Armour and Fanatics is scheduled to begin in 2020 and run for 10 years, but sources say it could start before that should Majestic decide to bow out early.

Under the terms of the deal, Under Armour will make all on-field apparel, including jerseys and game-day and training outerwear, that is currently made by Majestic, and base-layer gear that is made by Nike.

Fanatics, the largest sports retailer, will make the merchandise that will be sold to fans, serving as both the producer and the seller.

Fanatics Inc. and MLB announced an agreement in December that gave the company licensing rights to manufacture and distribute merchandise starting in 2020. Fanatics signed a deal last month to buy VF Corp.'s Licensed Sports Group and with it the 600-worker Majestic Athletic plant in Easton, Pennsylvania, where team jerseys and fan apparel are manufactured.

Baseball Commissioner Rob Manfred said Thursday that fan merchandise from Under Armour will be available next year and that Under Armour will be worn for dugout clothing during the 2018 postseason. The full switch to Under Armour for on-field apparel will take place for the 2019 season.

Majestic has manufactured MLB batting practice jerseys since 1982 and has been the exclusive supplier of game uniforms since 2005. Before that, uniforms were manufactured by both Majestic and Russell.

BUY with stop loss at $3.99

RSI(14) 8.58 That must be a record.

This report looks good. Not sure about margins. Do not follow this company.

GenMark Diagnostics Reports Third Quarter 2017 Results

Genmark Diagnostics, Inc. (MM) (NASDAQ:GNMK)

Saturday 4 November 2017

GenMark Diagnostics, Inc. (Nasdaq:GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced financial results for the third quarter ended September 30, 2017.

Third Quarter Highlights

Placed 65 ePlex® analyzers in the third quarter, mostly driven by first full quarter of U.S. launch

Finished the quarter with an installed base of 147 ePlex analyzers in U.S. and European labs

Achieved revenues of $11.6 million in the quarter, an increase of 7.3% over the prior year period

“We are pleased with our first full quarter of ePlex launch in the U.S., which drove the majority of placements in the third quarter,” said Hany Massarany, President and Chief Executive Officer. “With strong sales funnels and continued positive customer feedback regarding the overall performance of ePlex, we remain optimistic about our opportunity to accelerate our revenue growth rate and capture market share in the global multiplex molecular diagnostics market.”

Third Quarter Financial Results

Revenue was $11.6 million in the third quarter of 2017, an increase of 7.3% versus $10.7 million in the third quarter of 2016. Gross profit was $4.2 million, or 36% of revenue, compared with $6.5 million, or 60% of revenue in the same period of 2016.

Operating expenses for the third quarter of 2017 were $18.9 million compared to $18.1 million in the same period for 2016. The increase was mainly driven by sales and marketing expenses as the Company continues to expand its commercial organization in support of the global ePlex product launch.

Loss per share was $0.28 per share for the third quarter of 2017, compared to a $0.27 loss per share in the third quarter of 2016.

The Company ended the quarter with $86.9 million in cash and investments.

Business Outlook

For full year 2017, GenMark expects revenue to range from $51 - $53 million and gross margin to range from 38% to 40%. The Company expects to exit 2017 with 185-200 ePlex placements.

AMD turned out good.

UAA

short?

https://www.msn.com/en-us/money/companies/sears-depletes-dollar200-million-loan-in-latest-sign-of-cash-burn/ar-AAufiT3?ocid=spartandhp

BUY

CDE Couer Mining

EGO Eldorado Mining

AMD Advanced Micro Devices

MOMO Momo Chinese Internet

TRVG Trivago Leasure

$MEDT: $.000x play~ it's endorsed by rappers! POS is deeply undervalued!

***** $CHRO: ****** $mart MMs/brokerages would load up & go long...Why? This has a PPS of $1.00s+ written all over!!!

Spend 30-60 minutes to read the DDs & watch the related videos & one will see the potential of this stock! Wait & see...Institutional buyers/investors will take this to silver land & then dollar land! *****

Google's Acquisition of Nest Closes the Loop on the Smart Home

$SURE, $VGID, $GNPT: aiming for $.00x

$COBI: could be a 10-50x bagga in the long-run

Apyp

$CHRO: This is how CHRO Longs (supporters, believers, ask-slappers) beat up un-neuter MM-CSTI~

$CHRO: $.0389s...& achieving .04s marks our first milestone to the path of $.25s+!


- Go CHRO

NSFC Chart bouncing off the 50 DMA. Those 2 shares that sold today at 0.57 dipped to the 50DMA and closing at 0.59 looks like the uptrend is still in tact Golden Cross still coming up.

Keep an eye out on $GLDG

$LUSI, $FRGY, $ITCJ: 1s play

$VAPE trying to make a run

As I am convinced that $IDGC as things progresses are going to improve for this particular company in the foreseeable future, an by all means DD and don't take my word for it. But put it on your radar.

We could be presented with something at bottom levels and positioned for a strong reversal.

http://www.otcmarkets.com/stock/IDGC/financials#

IJJP - good to keep on watch it's hit bottom, has reduced share price last month so no dilution , good financials last quarter, been shorted heavily, so will need to cover, just waiting on update, plus not a lot of debt. :)

IDNG worth a look folks.

$DSCR: Majority & minority leaders of both parties support industrial hemp more than MJ~ Most federal gov't of major countries also tend to support industrial hemp more...examples: Canada, Australia, China, Japan, India, Russia, etc.


http://www.hempuniversity.com/hemp-university/growing-hemp/countries-growing-hemp/

In Canada:

$DSCR: The Power of Hemp and its countless uses

$HPNN: Hop-on Shareholder Meeting Update
Date : 05/20/2014 @ 1:45PM
Source : Marketwired
Stock : Hop-on, Inc. (PC) (HPNN)


Hop-on Shareholder Meeting Update

Hop-on Identifies 170 OEMs and ODMs for IP Licensing

TEMECULA, CA--(Marketwired - May 20, 2014) - Hop-on, Inc. (OTC Pink: HPNN) (PINKSHEETS: HPNN) a global electronics OEM, is pleased to announce today that its shareholder meeting held on May 16, 2014 was a successful opportunity to interact with shareholders regarding recent developments. The format of the meeting allowed for an open and broad-ranging discussion to address Company progress and concerns.

The Company has put out several news releases in recent months, and the purpose of the shareholder meeting was to review the Company's positive developments and lay out the plans for its future.

The agenda items covered were

1. Update on the intellectual property royalty agreement with Microsoft.

2. Closing of the Company's first IPR deal with Teleepoch

3. Update on IPR negotiations with 12 Chinese and Taiwanese OEMs

4. Update on 170 companies Hop-on will be pursuing for licensing arrangements

5. Retirement of significant portions of Company debt

6. Plans for spin-off of Re-Medical subsidiary to fully reporting public BB company

7. CTO summarized Re-Medical's proprietary cannabinoid therapies and delivery technologies

8. Plans for Re-Medical IP licensing arrangements and operations in Colorado

9. Plans for USACig subsidiary

10. Plans for adjusting the capital structure of the Company, including dispelling false rumors of a pending reverse stock split

11. At the insistence of shareholders, Mr. Michaels addressed concerns regarding a stalker harassing him using different aliases on the Internet. Mr. Michaels acknowledged in response to shareholder concerns that law enforcement is investigating this individual. The shareholders were also informed regarding status of an extortion attempt by one internet poster earlier this year.

Peter Michaels, President of Hop-on stated, "I was pleased with our shareholder turnout at the meeting, and even more pleased about the positive response and outlook of our investors. I also appreciate the support from our shareholders."

ABOUT HOP-ON, INC.
Hop-on, Inc. is a global ODM and OEM manufacturer of electronics, based in the United States. Over the past 20 years, Hop-on has successfully secured essential patents for mobile communications and computing technologies, and is respected for developing the world's first disposable cell phone. Hop-on's focus on smartphones and innovative mobile device applications is bringing cost friendly solutions to today's demanding world market. Hop-on is also diversified in nutraceutical and cannabinoid technologies through its subsidiary Re-Medical, Inc. For more information, please visit www.hop-on.com and www.re-medical.com

Safe Harbor
This press release contains forward looking statements pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements include risks and uncertainties that may cause the company's plans to change and are in no way intended to guarantee that the company will be successful in executing its plans. Hop-on, Inc. common stock currently trades on the over-the-counter "Pink Sheets" under the symbol HPNN. This press release in no way constitutes any recommendation regarding the securities of HPNN or its affiliates. Any person reading this press release is advised that this release should be considered in the light of all facts and circumstances regarding the business and financial condition and prospects of HPNN, and no inference has been made that this release contains all such information.

Additional Information
For additional information, please contact
Peter Michaels
(949) 756-9008
Email contact@hop-on.com



- Go HPNN

Playing DSCR is like playin' "Who wants to win an Ounce? "

$HPNN: Hop-on and United Cannabis Sign Contract
Date : 05/19/2014 @ 11:40AM
Source : Marketwired
Stock : Hop-on, Inc. (PC) (HPNN)


Hop-on and United Cannabis Sign Contract

Re-Medical Finds Partner for Standardized Strains, Regional Production

TEMECULA, CA--(Marketwired - May 19, 2014) - Hop-on, Inc. (OTC Pink: HPNN) (PINKSHEETS: HPNN) is pleased to announce today that an agreement has been reached with United Cannabis Corporation, Inc. (UCANN) (OTC Pink: CNAB) (PINKSHEETS: CNAB) to assist with a regional rollout in the multibillion dollar Cannabis market utilizing their licensed partners' prolific catalog of award winning CBD-dominant and THC:CBD strains and world class cultivation expertise.

UCANN was selected as a strategic partner for their expertise in the medical and recreational Cannabis marketplace, their numerous regional partners that are state licensed and have been vetted for quality, consistency, and business ethics, and the fact that they are actively expanding from Colorado to other markets as they become viable. UCANN will assist in provisioning exclusive Cannabis cultivars that meet the stringent needs of Re-Medical's standardized cannabinoid profiles, and provide assistance in the build-out of processing, extraction, and production facilities, and regional sales and distribution operations for Re-Medical's cannabinoid therapies.

Re-Medical will provide licensing of intellectual property, where appropriate, regarding standardized cannabinoid profiles that show empirical or clinical efficacy as treatment for specific ailments, standardized cannabinoid profile extraction methods, efficient extraction of active ingredients from Cannabis using supercritical CO2 fluid extraction technologies, and the formulation and fabrication of transdermal and other innovative cannabinoid delivery technologies.

The market for CBD and other cannabinoid therapies is just beginning to be tapped, with over $600 million in annual sales expected this year in Colorado alone. With the entrance of more regions into the self-regulated cannabis marketplace, and the use of curated strains, professional production and processing methods, and rigorous testing standards, the market currently valued at $1.53 billion is projected to grow 68% to $2.57 billion by the end of 2014.

Peter Michaels, Hop-on CEO, stated, "As strategic partners, Re-Medical and UCANN have the combined resources, experience, and intellectual property to fulfill the longstanding dreams of many who have suffered far too long in a marketplace without standards. Together, we bring a force for quality, safety, efficacy, and a true passion to end needless suffering. It's an amazing thing when what's great for business is also great for society."

About Hop-on, Inc.
Hop-on, Inc. is a global ODM and OEM manufacturer of electronics, based in the United States. Over the past 20 years, Hop-on has successfully secured essential patents for mobile communications and computing technologies, and is respected for developing the world's first disposable cell phone. Hop-on's focus on smartphones and innovative mobile device applications is bringing cost friendly solutions to today's demanding world market. Hop-on is also diversified in nutraceutical and cannabinoid technologies through its subsidiary Re-Medical, Inc. For more information, please visit www.hop-on.com and www.re-medical.com

About UCANN
United Cannabis Corporation has a foundation in the cannabis industries. With our consulting services, management and oversight we are capable of assisting any Cannabis oriented company on any scale. United Cannabis Corporation is now partnering domestically and internationally with local businessmen, entrepreneurs, scientists, and government agencies for the purpose of promoting Best Practices in Planning, Procedures, Governance and Patient Care. Consulting and providing guidance on design and construction of growth facilities and cultivation of medical grade cannabis-based products worldwide. With access to a catalog of award winning genetics and coupled with our leadership & experience we are positioned to take any Cannabis Business through all of the steps for success. For further information, please visit www.unitedcannabis.us

Forward-Looking Statements
Certain statements in this news release may contain forward-looking information within the meaning of Rule 175 under the Securities Act of 1933, and are subject to Rule 3B-6 under the Securities Exchange Act of 1934, and are subject to the safe harbor created by those rules. All statements, other than statements of fact, included in this release, including, without limitation, statements regarding potential future plans and objectives of the company, are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and other results and further events could differ materially from those anticipated in such statements. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements.

Additional Information
For additional information, please contact
Shareholder Services
(949) 756-9008
Email contact@hop-on.com



- Go HPNN

$PTAH : HUGE NEWS AHEAD

$IDGC: ID Global Corporation Retains International Creative Licensing, LLC to Assist in Intellectual Property Valuation
Date : 06/10/2014 @ 7:00AM
Source : PR Newswire (US)
Stock : Idglobal Corp. (PC) (IDGC)

CHICAGO, June 10, 2014 /PRNewswire/ -- ID Global Corp. (OTC: IDGC) is pleased to announce that IDGC has retained International Creative Licensing, LLC., an intellectual property firm, to assist in valuation and licensing of its Intellectual Property (IP) of current portfolio companies. The first company, Jack Rockwell, Inc., currently holds multiple patents for its Farquest™ Machine and is exploring several opportunities regarding its IP.

Sebastien DuFort, president and CEO stated "We are excited to engage a firm that has the ability to help with the valuation process of our portfolio companies assets. This will be a key process in vetting current and future intellectual property to ensure our investment capital sees a return."

About International Creative Licensing, LLC.

International Creative Licensing (ICL) is a boutique licensing and consulting firm specializing in intellectual property portfolio management and brand valuation. Founder Bill Uglow, former Disney executive and Todd Uglow, court approved expert witness in the area of right of publicity law and intellectual property valuation have worked on hundreds of IP projects. Past and present clients include, but are not limited to, Disney, LucasFilm, and the four major US sports leagues; most recently the National Football League.

About ID Global Corporation

ID Global Corporation (IDGC) is a diversified holdings company with a focus on emerging and middle market investment opportunities in North America. IDGC seeks, through debt and equity investments, controlling interests in established companies as well as special situation start-ups.


- Go IDGC

$DSCR: Discovery's Bio-Fuel Joint Venture Acquires Exclusive License
Date : 04/29/2014 @ 8:00AM
Source : PR Newswire (US)
Stock : Discovery Minerals Ltd. (PC) (DSCR)

RENO, Nevada, April 29, 2014 /PRNewswire/ -

Discovery Minerals LTD. (OTC: DSCR) is pleased to announce that its Joint Venture (JV) with Syngar Technologies is to be extended an exclusive North American license with Cellunol Inc. The Agreement allows the JV use of Cellunol's pre-treatment Bio-Fuel fermentation technology for all Hemp Sector applications.

Cellunol Inc. was formed as a Joint Venture between ANW Inc. of South Africa and Syngar Technologies. ANW's proprietary fermentation tank design and cellulosic pre treatment technology, Oxy-Hydro Fragmentation, when coupled with Syngar's technology, known as PLUSWave, solves one of the major issues in ethanol production from cellulose. This solutions result is an industry first, low cost cellulose pre treatment and fermentation system that is portable. The system is set up directly on the growing site or near the cellulose collection point and works similar to a grain elevator.

Discovery's Joint Venture will be the first company to evaluate this ground breaking system through their Industrial Hemp JV growing partners. This new system has the ability to process any unused hemp material in one continuous procedure from pre-treatment to sugar to ethanol. The systems efficiencies will result in significantly reduced up front capital costs and lower operational expenses while enhancing ethanol yields and net revenue.

About ANW Inc.:

ANW is a private South African based company that has developed and owns a proprietary cellulose pre treatment technology and fermentation tank designs that can rapidly pre-treat cellulose materials into a slurry product suitable for fermentation by yeasts into ethanol. Their Oxy-hydro technologies can rapidly breakdown plant material without the use of stream, pressure, or dangerous acids.

About Syngar and PLUSWave:
The Company is a private Canadian company based in Edmonton, Alberta. Syngar licensed a technology, which we call "Pulsed Low Ultra Sound Wave" (PLUSWave) Technology. The PLUS Wave[TM] license is a worldwide and exclusive for application in biofuels. The PLUSWave Technology uses specific and proprietary ultrasound frequencies, at specific power levels, over set time intervals to stimulate the fermentation growth of algae, bacteria, fungus or yeast microorganisms by upwards of 30 - 50%.
About Discovery Minerals LTD.:

Discovery Minerals Ltd., (OTC: DSCR) is a production stage company formed to acquire and develop natural resource properties. Activities include gold, precious metals and petroleum minerals, including rare earth minerals production and sales. The Company initiated a new program to evaluate undervalued assets, including clean tech and alternative energy investments, for potential addition to its portfolio.

Safe Harbor: This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 27E of the Securities Act of 1934. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties including, without limitation, ability to obtain financing and regulatory and shareholder approval for anticipated actions.

Contact Person:
Bill McNerney
+1(310)961-4654
At: info@discoveryholdingscorp.com

- Go DSCR

GNCP could be a quick flipper....

GNCC Capital, Inc. Restored to Current Filer Status Business Wire   "Press Releases - English"
NEW YORK --(BUSINESS WIRE)-- GNCC Capital, Inc. (OTC: GNCP) (The Company) was today restored to that of a CURRENT INFORMATION FILER on the OTC Markets.

The Company is now current in all of its filings on the OTC Markets.

The Companys Annual Report for the year ended September 30, 2014 will be filed on or before December 31, 2014 , in order for the Company to remain as a CURRENT INFORMATION FILER on the OTC Markets.

Peter Voss , the recently appointed Group Chief Executive Officer, will be updating stockholders next week on the Companys existing operations and on further acquisitions.

About GNCC Capital, Inc. :

GNCC Capital, Inc. is a Holding Company which at present has a number of subsidiary companies which are engaged in Adult Social Gaming Arcades in South Florida and in Mining Exploration.

The Companys Gold & Silver Mining Exploration properties are located in Arizona and consist of McCracken, Alamo, North Rawhide, White Hills , Esther Basin , Burnt Well, Clara, Kit Carson , Silverfields and Potts Mountain ".

The Company intends to continue to diversify into other Industry Sectors through acquisitions.

$SFOR DAILY CHART

$SFOR is FOR IT!!!